Development of a human breast-cancer derived cell line stably expressing a bioluminescence resonance energy transfer (BRET)-based phosphatidyl inositol-3 phosphate (PIP3) biosensor.

Abstract : Stimulation of tyrosine kinase receptors initiates a signaling cascade that activates PI3K. Activated PI3K uses PIP2 to generate PIP3, which recruit Akt to the plasma membrane through its pleckstrin homology (PH) domain, permitting its activation by PDKs. Activated Akt controls important biological functions, including cell metabolism, proliferation and survival. The PI3K pathway is therefore an attractive target for drug discovery. However, current assays for measurement of PIP3 production are technically demanding and not amenable to high-throughput screening. We have established a MCF-7-derived breast cancer cell line, that stably co-expresses the PH domain of Akt fused to Renilla luciferase and YFP fused to a membrane localization signal. This BRET biosensor pair permits to monitor, in real time, in living cells, PIP3 production at the plasma membrane upon stimulation by different ligands, including insulin, the insulin analogue glargine, IGF1, IGF2 and EGF. Moreover, several known inhibitors that target different steps of the PI3K/Akt pathway caused inhibition of ligand-induced BRET. Cetuximab, a humanized anti-EGF receptor monoclonal antibody used for the treatment of cancer, completely inhibited EGF-induced BRET, and the tyrosine kinase inhibitor tyrphostine AG1024 inhibited insulin effect on PIP3 production. Moreover, the effects of insulin and IGF1 were inhibited by molecules that inhibit PI3K catalytic activity or the interaction between PIP3 and the PH domain of Akt. Finally, we showed that human serum induced a dose-dependent increase in BRET signal, suggesting that this stable clone may be used as a prognostic tool to evaluate the PI3K stimulatory activity present in serum of human patients. We have thus established a cell line, suitable for the screening and/or the study of molecules with stimulatory or inhibitory activities on the PI3K/Akt pathway that will constitute a new tool for translational research in diabetes and cancer.
Type de document :
Article dans une revue
PLoS ONE, Public Library of Science, 2014, 9 (3), pp.e92737. 〈10.1371/journal.pone.0092737〉
Liste complète des métadonnées

Littérature citée [61 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01067930
Contributeur : Mireille Bos <>
Soumis le : mercredi 24 septembre 2014 - 12:42:45
Dernière modification le : jeudi 11 janvier 2018 - 06:23:10
Document(s) archivé(s) le : jeudi 25 décembre 2014 - 10:50:37

Fichier

pone.0092737.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

Citation

Mei-Shiue Kuo, Johanna Auriau, Cécile Pierre-Eugène, Tarik Issad. Development of a human breast-cancer derived cell line stably expressing a bioluminescence resonance energy transfer (BRET)-based phosphatidyl inositol-3 phosphate (PIP3) biosensor.. PLoS ONE, Public Library of Science, 2014, 9 (3), pp.e92737. 〈10.1371/journal.pone.0092737〉. 〈inserm-01067930〉

Partager

Métriques

Consultations de la notice

261

Téléchargements de fichiers

177